OnDosis

OnDosis Dosage Manager delivers flexible and individualized dosing of oral medicines formulated as pellets, granules, mini tablets or powders. We are writing a new chapter in personalized medicine, and enable closed loop disease management. OnDosis is currently developing products for individualized dosing in diseases with a significant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes. OnDosis was founded as a spin-out from AstraZeneca in 2017 and is headquartered in Gothenburg, Sweden.